AEGLEA BIOTHERAPEUTICS INC's ticker is AGLE and the CUSIP is 00773J103. A total of 72 filers reported holding AEGLEA BIOTHERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2019 | $81,000 | -34.7% | 10,659 | -33.6% | 0.00% | -33.3% |
Q3 2019 | $124,000 | -67.2% | 16,061 | -70.9% | 0.00% | -62.5% |
Q2 2019 | $378,000 | +182.1% | 55,116 | +231.3% | 0.01% | +166.7% |
Q1 2019 | $134,000 | -60.4% | 16,637 | -53.1% | 0.00% | -57.1% |
Q3 2018 | $338,000 | -62.4% | 35,447 | -58.0% | 0.01% | -58.8% |
Q2 2018 | $899,000 | +945.3% | 84,315 | +372.9% | 0.02% | +750.0% |
Q3 2017 | $86,000 | +79.2% | 17,831 | +43.8% | 0.00% | +100.0% |
Q2 2017 | $48,000 | – | 12,399 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
UNIVERSITY OF TEXAS/TEXAS AM INVESTMENT MANAGEMENT CO | 279,678 | $2,587,000 | 10.00% |
Aisling Capital Management LP | 1,691,151 | $15,643,000 | 5.97% |
Samsara BioCapital, LLC | 967,500 | $8,949,000 | 2.88% |
Bain Capital Life Sciences Investors, LLC | 2,700,000 | $24,975,000 | 2.62% |
Soleus Capital Management, L.P. | 369,852 | $3,421,000 | 1.95% |
Nantahala Capital Management | 3,204,830 | $29,645,000 | 0.89% |
Lion Point Capital, LP | 300,000 | $2,775,000 | 0.67% |
Abingworth LLP | 240,500 | $2,221,000 | 0.62% |
Sio Capital Management, LLC | 211,104 | $1,953,000 | 0.57% |
Orbimed Advisors | 4,015,524 | $37,144,000 | 0.52% |